Product
QR-421a
1 clinical trial
8 indications
Indication
Retinitis PigmentosaIndication
Usher syndrome type 2Indication
Deaf-BlindIndication
Retinal DiseaseIndication
Eye DisordersIndication
HereditaryIndication
Congenital Eye DisordersIndication
Vision DisordersClinical trial
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision LossStatus: Terminated, Estimated PCD: 2022-08-02